Thomas Unise
Beijing-based Surgerii Robotics has closed a $100 million Series D financing round to expand marketing of its SHURUI single-port surgical robot and accelerate development of next-generation products. The company’s innovative system has achieved significant regulatory milestones and clinical adoption.
SHURUI: A Breakthrough in Single-Port Surgery
The SHURUI single-port endoscopic surgical system (SR-ENS-600) represents a significant advancement in minimally invasive surgery. The company claims it is “the world’s first commercially available single-port surgical robot with snake-like instruments,” enabling complex procedures through a single 1.8 cm incision.
The technology is built on the “Dual Continuum Mechanism” design developed by Professor Kai Xu of Shanghai Jiao Tong University. This innovation allows for highly precise and complex surgical procedures with minimal invasiveness.
Regulatory Achievements and Applications
SHURUI has secured several important regulatory approvals:
- China’s National Medical Products Administration (NMPA) approval in June 2023
- CE certification in Europe in August 2025
The system is currently approved for urology and gynecology laparoscopic surgeries for both benign and malignant conditions. Applications in general surgery and thoracic surgery are under review in some markets.
Notably, Surgerii claims SHURUI is the only CE-certified single-port surgical robot approved for pediatric use and the first Chinese surgical robot certified for patients of all age groups.
Clinical Impact and Adoption
Surgerii has established clinical partnerships with over 70 Grade A tertiary hospitals in China. The SHURUI system has been used in more than 3,000 surgeries domestically and nearly 50 procedures internationally. The company has developed over 80 surgical techniques addressing clinical gaps across Asia or China.
These procedures range from complex cancer operations to surgeries on pediatric patients as young as 7 days old, demonstrating the system’s versatility and potential to reduce surgical trauma across a broad patient population.
Investment and Future Growth
The $100 million Series D round was led by Loyal Valley Capital, with participation from Shanghai Healthcare Capital, V Star Capital, DNV Capital, and Hefei Industrial Investment. This funding will support:
- Deeper market penetration in China
- Accelerated international commercialization
- Development of advanced energy instruments
- Creation of disruptive systematic solutions centered on cutting-edge technology
In 2025, Surgerii established the European Clinical Excellence Center in collaboration with IRCAD, a leading institution for minimally invasive surgical training, highlighting its strategic focus on the European market.
Intellectual Property Position
During the financing process, investors conducted a comprehensive review of Surgerii’s intellectual property, comparing SHURUI SP with over 3,000 valid patents held by leading endoscopic surgical robot companies across Europe and the U.S.
Despite the crowded patent landscape, Surgerii claims its robot “has achieved disruptive innovation and breakthroughs in key technologies” that are significantly distinguished from existing surgical patents, providing a solid foundation for international commercialization.
Conclusion
Surgerii Robotics is positioning its SHURUI single-port surgical robot as a significant advancement in minimally invasive surgery. With substantial financial backing, regulatory approvals in key markets, and growing clinical adoption, the company appears well-positioned to challenge established players in the surgical robotics space while expanding access to minimally invasive surgical options.
GIPHY App Key not set. Please check settings